Everolimus after liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial studies a drug called everolimus given after liver cancer surgery to see if it helps prevent the cancer from returning. Everolimus is a pill that may help stop cancer cell growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Had surgery to remove liver cancer
- Are at high risk of the cancer coming back
- No prior cancer treatment before surgery
- No immunotherapy treatments before surgery
- Have adequate kidney function
- No significant fluid in the belly (ascites)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
This trial tests a combination of two drugs—everolimus, which may slow cancer growth, and a PD-1 inhibitor, which helps the immune system fight cancer—for people with advanced colorectal cancer that has progressed after standard treatments. The goal is to see if the combination can shrink or control the cancer.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Hear when a new Carcinom trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.